HER2 GENE MUTATION
Clinical trials for HER2 GENE MUTATION explained in plain language.
Never miss a new study
Get alerted when new HER2 GENE MUTATION trials appear
Sign up with your email to follow new studies for HER2 GENE MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted drug trial aims to stop rare Cancer's return
Disease control Recruiting nowThis study is testing whether adding the drug T-DM1 to standard radiation and chemotherapy after surgery can help prevent cancer from coming back in people with HER2-positive salivary gland cancer. The drug specifically targets cancer cells that have the HER2 protein. About 55 pa…
Matched conditions: HER2 GENE MUTATION
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Radioactive cancer drug enters first human tests
Disease control Recruiting nowThis is a very early study to test the safety and find the right dose of a new radioactive drug called 177Lu-RAD202 for people with advanced HER2-positive solid tumors. The study will enroll about 30 adults whose cancer has progressed after standard treatments. First, a small 'im…
Matched conditions: HER2 GENE MUTATION
Phase: EARLY_PHASE1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New drug duo tested for Tough-to-Treat stomach cancers
Disease control Recruiting nowThis is an early safety study to find the right dose of two drugs, neratinib and fam-trastuzumab deruxtecan, when given together. It's for adults with advanced stomach, esophageal, or other gastrointestinal cancers that have a specific marker called HER2 and have worsened after a…
Matched conditions: HER2 GENE MUTATION
Phase: PHASE1 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Cancer center tests Triple-Threat treatment to shrink tumors before surgery
Disease control Recruiting nowThis study is testing whether adding two newer drugs (pembrolizumab and trastuzumab) to standard chemotherapy before surgery can better control HER2-positive stomach and esophageal cancers. The goal is to shrink tumors before surgery and prevent cancer from returning. About 49 pa…
Matched conditions: HER2 GENE MUTATION
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC